Information Provided By:
Fly News Breaks for May 17, 2016
MDXG, OSIR
May 17, 2016 | 09:58 EDT
After MiMedx (MDXG) announced that it has filed suit against Osiris (OSIR), asserting that Osiris "knowingly and willfully made false and misleading representations," Piper Jaffray analyst Edward Tenthoff said it is unclear at this time what merit the claims have, but added that the lawsuit represents "yet another" overhang for Osiris shares. Noting that he expects BioSurgery sales to return Osiris to profitability, Tenthoff maintains an Overweight rating and $12 price target on the stock.